30th Jul 2014 09:45
LONDON (Alliance News) - Tissue Regenix Group PLC said Wednesday that it has received approval from the Medicines and Healthcare Products Regulatory Agency to start the first UK clinical trial of its dCELL meniscal device for knee repairs.
It expects the trial to begin in the fourth quarter of 2014, after it completes final tests and preparations.
Tissue Regenix said the approval "marks a critical stage" in getting EU clearance and a CE mark, which will allow it to fully commercialise the dCELL meniscus products.
The device is used to repair damage from tears in the meniscus knee cartilage from injury or degeneration.
Shares in Tissue Regenix were trading up 0.9% at 27.75 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group